1. Minimal residual disease (MRD) detection in acute lymphoblastic leukaemia based on fusion genes and genomic deletions
- Author
-
Monique L. den Boer, Harma Feitsma, Reno Bladergroen, Edwin Sonneveld, Roland P. Kuiper, Vincent H.J. van der Velden, Irina Sergeeva, Freerk van Dijk, Judith M. Boer, Frank N. van Leeuwen, P G Hoogeveen, Immunology, and Pediatrics
- Subjects
Neoplasm, Residual ,biology ,business.industry ,Hematology ,Precursor Cell Lymphoblastic Leukemia-Lymphoma ,Minimal residual disease ,Polymerase Chain Reaction ,law.invention ,Fusion gene ,Risk groups ,law ,hemic and lymphatic diseases ,Cancer research ,biology.protein ,Lymphoblastic leukaemia ,Medicine ,Humans ,Oncogene Fusion ,Antibody ,business ,Child ,Gene ,Polymerase chain reaction ,Gene Deletion - Abstract
Minimal residual disease (MRD) diagnostics are implemented in most clinical protocols for patients with acute lymphoblastic leukaemia (ALL) and are mostly performed using rearranged immunoglobulin (IG) and/or T-cell receptor (TR) gene rearrangements as molecular polymerase chain reaction targets. Unfortunately, in 5–10% of patients no or no sensitive IG/TR targets are available, and patients therefore cannot be stratified appropriately. In the present study, we used fusion genes and genomic deletions as alternative MRD targets in these patients, which retrospectively revealed appropriate MDR stratification in 79% of patients with no (sensitive) IG/TR target, and a different risk group stratification in more than half of the cases.
- Published
- 2021